Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2015 / Article

Case Report | Open Access

Volume 2015 |Article ID 602462 |

Christopher D. Cortes, Carl Urban, Glenn Turett, "Actinomyces naeslundii: An Uncommon Cause of Endocarditis", Case Reports in Infectious Diseases, vol. 2015, Article ID 602462, 4 pages, 2015.

Actinomyces naeslundii: An Uncommon Cause of Endocarditis

Academic Editor: Sandeep Dogra
Received21 Sep 2015
Accepted16 Nov 2015
Published30 Nov 2015


Actinomyces rarely causes endocarditis with 25 well-described cases reported in the literature in the past 75 years. We present a case of prosthetic valve endocarditis (PVE) caused by Actinomyces naeslundii. To our knowledge, this is the first report in the literature of endocarditis due to this organism and the second report of PVE caused by Actinomyces.

1. Introduction

Actinomyces naeslundii is a Gram positive anaerobic bacillary commensal of the human oral cavity. Septicemia with this organism is uncommon and poses an increased risk of subacute and chronic granulomatous inflammation, which can affect all organ systems via hematogenous spread [1]. We discuss a rare case of endocarditis caused by this organism.

2. Case Presentation

A 51-year-old Hispanic woman, with a history of hypothyroidism, asthma, and aortic stenosis requiring a bioprosthetic aortic valve replacement, presented with fever, nausea, and a 23-pound weight loss over the prior two months. The valve was excised at another hospital prior to patient’s presentation to us and no pathology information was available. She also complained of diffuse myalgias, erythematous lesions over the arms and legs, and clouded vision. One month prior to aortic valve replacement, she had dental implants inserted. Her symptoms began two months after valve replacement surgery. Physical examination on presentation was notable for a febrile ( F) woman in mild distress, but hemodynamically stable. Pertinent findings included poor dentition with apparent tooth decay and fracture below the gum line of two adjacent teeth, small punctate lesions over her upper and lower extremities, Roth spots on ophthalmoscopic exam, a well-healed sternotomy scar, and a grade III/VI holosystolic decrescendo murmur. Abnormal laboratory tests included a WBC count of 16.5 K/μL (reference range: 4.8–10.8 K/μL) with 88.5% neutrophils and C-reactive protein (CRP) 7.02 mg/L (reference range: 0.03–0.49 mg/dL). Only one set of blood cultures was drawn prior to empirically starting vancomycin and ceftriaxone (the patient had a vague history of a nonlife threatening penicillin allergy). The aerobic bottle showed bacterial growth at 26.3 hours and in the anaerobic bottle at 57.1 hours. They were subsequently inoculated on anaerobic blood agar and Brucella Laked Blood Agar with Kanamycin and Vancomycin (LKV). The isolate was identified as Actinomyces naeslundii by VITEK 2 ANC ID Card (BioMerieux) anaerobic and corynebacterium identification. Vancomycin was discontinued and ceftriaxone alone was used.

A transesophageal echocardiogram demonstrated trace mitral and tricuspid valve regurgitation, but no definitive vegetation. Repeat blood cultures drawn on day two of admission showed no growth and she defervesced within two days. After 7 days of treatment, her leukocytosis resolved and she was no longer symptomatic. No posttreatment echo was done seeing pretreatment and 10 days into treatment, studies showed no aortic valve dehiscence or regurgitation.

A CRP repeated after 21 days was 0.8 mg/L. Four weeks into therapy, ceftriaxone was changed to ertapenem due to a febrile reaction attributed to ceftriaxone. The patient received a total of sixteen weeks of appropriate intravenous antibiotic therapy. She was evaluated by an allergy/immunology specialist and was cleared to receive amoxicillin which then was started at a dose of 1 gram every 12 hours for a planned twelve-month total course of antibiotics. The patient also had her tooth extracted after discharge from the hospital and she follows up every six months with her dentist. Eight weeks later, she presented to the clinic for follow-up. She was well compliant with and tolerating amoxicillin. Surveillance blood cultures drawn then were sterile. Two weeks after completion of the twelve months of antibiotics, she remained well and surveillance cultures drawn on that visit remained negative.

3. Discussion

We present an unusual case of Actinomyces naeslundii endocarditis in an immunocompetent individual. According to the modified Duke’s criteria, our patient had 4 minor criteria classifying her condition as possible endocarditis. The likelihood of endocarditis was strengthened by recent dental work followed by aortic valve replacement surgery and ongoing poor dentation; persistent fevers two months after surgery; bacteremia with Actinomyces naeslundii, which is associated with early caries and tooth decay [2]; significant weight loss; evidence of immunologic sequelae (Roth spots) and an elevated inflammatory marker (CRP). Respecting the possibility of prosthetic valve endocarditis prompted aggressive treatment with an extended course of parenteral followed by oral antibiotics.

Actinomyces bacteremia is well described in the dental literature following dental procedures [3]. However, Actinomyces species rarely cause endocarditis. Actinomycosis is more commonly associated with cervicofacial, pelvic, and thoracic deep-seated infections. There is no specific recommended duration of therapy for Actinomyces endocarditis. For patients with deep-seated thoracic infections, 2 to 6 weeks of intravenous antibiotics are advised, followed by oral penicillins for six to twelve months [4].

An extensive review of the literature since 1939 revealed 24 well-described cases of endocarditis due to Actinomyces including six cases of Actinomyces species [59], two of Actinomyces bovis [10, 11], four of Actinomyces viscosus [1215], two cases of Actinomyces meyeri [16, 17], three of Actinomyces israelii [1820], two of Actinomyces neuii [21, 22], and one of each of Actinomyces septicus [23], Actinomyces muris [24], Actinomyces pyogenes [25], Actinomyces funkei [26], and Actinomyces odontolyticus [27] (Table 1). Almost half of these patients were noted to have predisposing cardiac pathology. One recent report described a case of eustachian valve endocarditis caused by Actinomyces turicensis [28]. Four of the 20 patients who received therapy died from pulmonary edema and acute respiratory failure. Three patients underwent aortic valve replacement surgery and survived. Most of the patients received a beta-lactam antibiotic (mainly penicillin), but few received other classes of antibiotics (glycopeptide, sulfonamide, aminoglycoside, and chloramphenicol). In 15 patients, duration of antibiotic therapy was stated and ranged from 24 days to 13 months (mean 21.4 weeks, median 16 weeks).


Uhr, 1939 [10]24 MActinomyces bovisAortic/MitralNoSulfathiazoleDead
Beamer et al., 1945 [5]55 MActinomyces sp.Aortic/MitralNoNoneDead
Blevins and Mac Neal, 1946 [23]UKActinomyces septicusMitralNoNoneUK
MacNeal et al., 1946 [6]39 MActinomyces sp.MitralNoPCNAlive
Wedding, 1947 [7]37 MActinomyces sp.MitralNoSulfathiazoleDead
Wedding, 1947 [7]71 FActinomyces sp.Aortic NoNoneDead
Stokes et al., 1951 [24]27 FActinomyces murisMitralNoChloramphenicolAlive
Walters et al., 1962 [11]43 FActinomyces bovisAortic/MitralNoPCNAlive
Dutton and Inclan, 1968 [18]6 MActinomyces israeliiMitralNoPCNDead
Gutschik, 1976 [12]70 MActinomyces viscosusMitralNoPCNAlive
Lam et al., 1993 [19]65 MActinomyces israeliiAortic/MitralNoPCNAlive
Moffatt et al., 1996 [16]48 MActinomyces meyeriAorticYes, AVRPCNAlive
Reddy et al., 1997 [25]64 MActinomyces pyogenesAorticNoMultipleDead
Hamed, 1998 [13]81 MActinomyces viscosusAorticNoCeftizoximeAlive
Huang et al., 1998 [17]55 MActinomyces meyeriMitralNoAmpicillin-sulbactamAlive
Mardis and Many Jr., 2001 [14]38 MActinomyces viscosusMitralNoMultiple, PCNAlive
Westling et al., 2002 [26]40 FActinomyces funkeiTricuspidNoMultipleAlive
Oh et al., 2005 [27]33 MActinomyces odontolyticusTricuspidNoCeftriaxone (CTX)Alive
Julian et al., 2005 [15]43 FActinomyces viscosusAorticYes, AVRAmp, CTX, and vancomycinAlive
Cohen et al., 2007 [21]68 MActinomyces neuiiAorticYes, AVRAmp, CTX, and gentamicinAlive
Oddó and Ayala, 2007 [8]34 MActinomyces sp.MitralNoUKDead
Grundmann et al., 2010 [22]66 MActinomyces neuiiAortic (prosthetic)NoPCNAlive
Adalja and Vergis, 2010 [20]87 MActinomyces israeliiMitralNoPCNAlive
Mehrzad et al., 2013 [9]49 MActinomyces sp.TricuspidNoMultipleAlive
Kottam et al., 2015 [28]30 FActinomyces turicensisEustachianNoMultiple, pen, and CTXAlive
Present Report51 FActinomyces naeslundiiAortic (prosthetic)NoVanco, CTX, ertapenem, and amoxicillinAlive

UK: unknown, PCN: penicillin, CTX: ceftriaxone, Amp: ampicillin, Gent: gentamicin, Vanc: vancomycin, Ert: ertapenem, and valve replacement surgery.

To our knowledge, this is the first case of Actinomyces naeslundii endocarditis reported in the literature to date and the second of prosthetic valve endocarditis caused by Actinomyces [22]. Grundmann et al. described a case of Actinomyces neuii prosthetic valve endocarditis also managed successfully with medical treatment alone (6-week intravenous regimen of penicillin followed by oral amoxicillin for 11 months) [22].

Similar to the treatment of other serious Actinomyces infections, endocarditis requires several weeks of intravenous antibiotic therapy, followed by six to twelve months of oral therapy. High doses of penicillin, for a prolonged period of time, remain the therapy of choice [29].

Conflict of Interests

All authors report no conflict of interests.

Authors’ Contribution

All authors contributed equally to this work.


  1. S. Abozaid, A. Peretz, W. Nasser, and Y. Zarfin, “Rare infection—prolonged A. naeslundii bacteremia caused by severe caries,” Harefuah, vol. 152, no. 7, pp. 379–435, 2013. View at: Google Scholar
  2. J. A. Aas, B. J. Paster, L. N. Stokes, I. Olsen, and F. E. Dewhirst, “Defining the normal bacterial flora of the oral cavity,” Journal of Clinical Microbiology, vol. 43, no. 11, pp. 5721–5732, 2005. View at: Publisher Site | Google Scholar
  3. F. K. Bahrani-Mougeot, B. J. Paster, S. Coleman, J. Ashar, S. Barbuto, and P. B. Lockhart, “Diverse and novel oral bacterial species in blood following dental procedures,” Journal of Clinical Microbiology, vol. 46, no. 6, pp. 2129–2132, 2008. View at: Publisher Site | Google Scholar
  4. J. Choi, W.-J. Koh, T. S. Kim et al., “Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis,” Chest, vol. 128, no. 4, pp. 2211–2217, 2005. View at: Publisher Site | Google Scholar
  5. P. R. Beamer, E. H. Reinhard, and I. I. Goodof, “Vegetative endocarditis caused by higher bacteria and fungi: review of previous cases and report of two cases with autopsies,” American Heart Journal, vol. 29, no. 1, pp. 99–112, 1945. View at: Publisher Site | Google Scholar
  6. W. J. MacNeal, A. Blevins, and A. W. Duryee, “Clinical arrest of endocardial actionomycosis after forty-four million units of penicillin,” American Heart Journal, vol. 31, no. 6, pp. 668–676, 1946. View at: Publisher Site | Google Scholar
  7. E. S. Wedding, “Actinomycotic endocarditis: report of two cases with a review of the literature,” Archives of Internal Medicine, vol. 79, no. 2, pp. 203–227, 1947. View at: Publisher Site | Google Scholar
  8. B. D. Oddó and R. F. Ayala, “Actinomycotic infective endocarditis of the mitral valve. Anatomoclinical case and review of literature,” Revista Chilena de Infectología, vol. 24, no. 3, pp. 232–235, 2007. View at: Google Scholar
  9. R. Mehrzad, M. Sublette, and M. Barza, “Polymicrobial endocarditis in intravenous heroin and fentanyl abuse,” Journal of Clinical and Diagnostic Research, vol. 7, no. 12, pp. 2981–2985, 2013. View at: Publisher Site | Google Scholar
  10. N. Uhr, “Bacterial endocarditis: report of a case in which the cause was Actinomyces bovis,” Archives of Internal Medicine, vol. 64, no. 1, pp. 84–90, 1939. View at: Publisher Site | Google Scholar
  11. E. W. Walters, M. J. Romansky, A. C. Johnson, and S. J. Conway, “Actinomyces bovis endocarditis: an uncommon and complex problem,” Antimicrobial Agents and Chemotherapy, vol. 2, no. 5, pp. 517–525, 1962. View at: Google Scholar
  12. E. Gutschik, “Endocarditis caused by Actinomyces viscosus,” Scandinavian Journal of Infectious Diseases, vol. 8, no. 4, pp. 271–274, 1976. View at: Publisher Site | Google Scholar
  13. K. A. Hamed, “Successful treatment of primary Actinomyces viscosus endocarditis with third-generation cephalosporins,” Clinical Infectious Diseases, vol. 26, no. 1, pp. 211–212, 1998. View at: Publisher Site | Google Scholar
  14. J. S. Mardis and W. J. Many Jr., “Endocarditis due to Actinomyces viscosus,” Southern Medical Journal, vol. 94, no. 2, pp. 240–243, 2001. View at: Publisher Site | Google Scholar
  15. K. G. Julian, L. de Flesco, L. E. Clarke, and L. J. Parent, “Actinomyces viscosus endocarditis requiring aortic valve replacement,” Journal of Infection, vol. 50, no. 4, pp. 359–362, 2005. View at: Publisher Site | Google Scholar
  16. S. Moffatt, A. R. Ahmen, and K. Forward, “First reported case of bacterial endocarditis attributable to Actinomyces meyeri,” Canadian Journal of Infectious Diseases, vol. 7, no. 1, pp. 71–73, 1996. View at: Google Scholar
  17. K.-L. Huang, S. M. Beutler, and C. Wang, “Endocarditis due to Actinomyces meyeri,” Clinical Infectious Diseases, vol. 27, no. 4, pp. 909–910, 1998. View at: Google Scholar
  18. W. P. Dutton and P. Inclan, “Cardiac actinomycosis,” Diseases of the Chest, vol. 54, no. 5, pp. 463–467, 1968. View at: Google Scholar
  19. S. Lam, J. Samraj, S. Rahman, and E. Hilton, “Primary actinomycotic endocarditis: case report and review,” Clinical Infectious Diseases, vol. 16, no. 4, pp. 481–485, 1993. View at: Publisher Site | Google Scholar
  20. A. A. Adalja and E. N. Vergis, “Actinomyces israelii endocarditis misidentified as ‘Diptheroids’,” Anaerobe, vol. 16, no. 4, pp. 472–473, 2010. View at: Publisher Site | Google Scholar
  21. E. Cohen, J. Bishara, B. Medalion, A. Sagie, and M. Garty, “Infective endocarditis due to Actinomyces neuii,” Scandinavian Journal of Infectious Diseases, vol. 39, no. 2, pp. 180–183, 2007. View at: Publisher Site | Google Scholar
  22. S. Grundmann, J. Huebner, J. Stuplich et al., “Prosthetic valve endocarditis due to Actinomyces neuii successfully treated with antibiotic therapy,” Journal of Clinical Microbiology, vol. 48, no. 3, pp. 1008–1011, 2010. View at: Publisher Site | Google Scholar
  23. A. Blevins and W. J. Mac Neal, “Actinomyces septicus from human endocarditis,” American Heart Journal, vol. 31, no. 6, pp. 663–667, 1946. View at: Publisher Site | Google Scholar
  24. J. F. Stokes, I. R. Gray, and E. J. Stokes, “Actinomyces muris endocarditis treated. with chloramphenicol,” British Heart Journal, vol. 13, no. 2, pp. 247–251, 1951. View at: Publisher Site | Google Scholar
  25. I. Reddy, D. A. Ferguson Jr., and F. A. Sarubbi, “Endocarditis due to Actinomyces pyogenes,” Clinical Infectious Diseases, vol. 25, no. 6, pp. 1476–1477, 1997. View at: Publisher Site | Google Scholar
  26. K. Westling, C. Lidman, and A. Thalme, “Tricuspid valve endocarditis caused by a new species of actinomyces: Actinomyces funkei,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 3, pp. 206–207, 2002. View at: Publisher Site | Google Scholar
  27. S. Oh, P. R. Havlen, and N. Hussain, “A case of polymicrobial endocarditis due to anaerobic organisms in an injection drug user,” Journal of General Internal Medicine, vol. 20, no. 10, pp. C1–C2, 2005. View at: Publisher Site | Google Scholar
  28. A. Kottam, R. Kaur, D. Bhandare et al., “Actinomycotic endocarditis of the eustachian valve: a rare case and a review of the literature,” Texas Heart Institute Journal, vol. 42, no. 1, pp. 44–49, 2015. View at: Publisher Site | Google Scholar
  29. T. A. Russo, “Agents of actinomycosis,” in Bennetts Principles and Practices of Infectious Diseases, J. E. Mandell, R. Douglas, and M. J. Blaser, Eds., Elsevier Saunders, Philadelphia, Pa, USA, 8th edition, 2015. View at: Google Scholar

Copyright © 2015 Christopher D. Cortes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.